StockData
Calidi Biotherapeutics, Inc. logo

Calidi Biotherapeutics, Inc. (CLDI) shareholders

CLDINYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as CLDWW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 3/30
$0.56−0.04 (-7.07%)

Close on Nov 17, 2026Market cap $1.45MP/E –Yield –

Ownership

Who owns Calidi Biotherapeutics's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 1 sales
Net sold $1.24K

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Kessler Judd S3,729,8425.00%13D (active)May 1, 2024
Armistice Capital, LLC
Joint filing with Steven Boyd (9.99%)
3,359,6619.99%13G (passive)Mar 31, 2025
Funicular Funds, LP
Joint filing with Cable Car Capital LLC (9.99%), Jacob Ma-Weaver (9.99%)
897,2419.99%13G (passive)Sep 4, 2024

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares ownedLatest filing
Santidrian Antonio FernandezChief Scientific Officer327,788Aug 19, 2026
Eric E. PomaChief Executive Officer25,000Aug 19, 2026
Andrew C. JacksonChief Financial Officer2,500Aug 19, 2026
James A. SchoeneckDirector84,514Aug 19, 2026
Alan R. StewartDirector28,976Aug 19, 2026
Corazon (Corsee) D. SandersDirector–Aug 19, 2026
Scott LeftwichDirector146,631Aug 19, 2026
George PeoplesDirector–Aug 19, 2026
Allan CamaisaDirector143,664Dec 16, 2025
Alternative Strategies LLC Lincoln10% owner730,000Aug 27, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Allan Camaisa
Director
Dec 12, 2025Sale−850$1.46$1.24K76,952
Andrew C. Jackson
Chief Financial Officer
Aug 21, 2025Buy+2,500$2.00$5.00K2,500
James A. Schoeneck
Director
Aug 21, 2025Buy+75,000$2.00$150.00K76,134
Scott Leftwich
Director
Aug 21, 2025Buy+125,000$2.00$250.00K130,650
Eric E. Poma
Chief Executive Officer, Director
Aug 21, 2025Buy+25,000$2.00$50.00K25,000
Alan R. Stewart
Director
Dec 31, 2024Award+12,771––28,976
Scott Leftwich
Director
Dec 31, 2024Award+11,684––67,774
Allan Camaisa
CEO and Chairman of the Board, Director
Dec 17, 2024Sale−10,000$1.62$16.20K66,712
Allan Camaisa
CEO and Chairman of the Board, Director, 10% owner
Sep 26, 2024Award+70,155$1.15$80.68K76,712
Scott Leftwich
Director
Jun 28, 2024Award+67,187––560,873
James A. Schoeneck
Director
Jun 28, 2024Award+79,687––1,071,781
Alan R. Stewart
Director
Jun 28, 2024Award+73,437––154,087
James A. Schoeneck
Director
Jun 3, 2024Option exercise+173,000$0.20$34.60K588,887
James A. Schoeneck
Director
Jun 3, 2024Option exercise+375,000$0.20$75.00K963,887
James A. Schoeneck
Director
Apr 18, 2024Award+375,000$0.40$150.00K415,887
James A. Schoeneck
Director
Mar 29, 2024Award+28,207––992,094
Alan R. Stewart
Director
Mar 29, 2024Award+25,995––80,650
Scott Leftwich
Director
Mar 29, 2024Award+23,783––493,686
Alan R. Stewart
Director
Dec 21, 2023Award+7,282$1.80$13.11K54,655
Scott Leftwich
Director
Dec 21, 2023Award+8,958$1.80$16.12K469,903
Alfonso G. Zulueta
Director
Dec 21, 2023Award+5,644$1.80$10.16K133,301
James A. Schoeneck
Director
Dec 21, 2023Award+10,625$1.80$19.13K27,872
Thomas A. Vecchiolla
Director
Dec 21, 2023Award+7,709$1.80$13.88K365,105
Thomas A. Vecchiolla
Director
Sep 12, 2023Conversion+6,000––6,000
FLAG Sponsor Manager, LLC
10% owner
Sep 12, 2023Conversion+1,931,852––1,931,852
Bay Capital Management LP Hudson
10% owner
Sep 12, 2023Other−500,000$10.49$5.25M0
Asset Management Partners Inc. Polar
10% owner
Oct 19, 2022Sale−36,200$9.90$358.38K412,800

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
2.5
At 0M shares a day
Change since last report
-17.4%
From 0M shares
Short volume, 20 days
28.5%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Calidi Biotherapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 56,182 shares on Sep 24, 2026 over the last 90 days.

See a number that looks wrong?